193 related articles for article (PubMed ID: 33926484)
1. Inhibition of CPT1a as a prognostic marker can synergistically enhance the antileukemic activity of ABT199.
Mao S; Ling Q; Pan J; Li F; Huang S; Ye W; Wei W; Lin X; Qian Y; Wang Y; Huang X; Huang J; Wang J; Jin J
J Transl Med; 2021 Apr; 19(1):181. PubMed ID: 33926484
[TBL] [Abstract][Full Text] [Related]
2. High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia.
Shi J; Fu H; Jia Z; He K; Fu L; Wang W
EBioMedicine; 2016 Dec; 14():55-64. PubMed ID: 27916548
[TBL] [Abstract][Full Text] [Related]
3. Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias.
Ricciardi MR; Mirabilii S; Allegretti M; Licchetta R; Calarco A; Torrisi MR; Foà R; Nicolai R; Peluso G; Tafuri A
Blood; 2015 Oct; 126(16):1925-9. PubMed ID: 26276667
[TBL] [Abstract][Full Text] [Related]
4. Targeting PI3K/AKT/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax.
Liu H; Hussain Z; Xie Q; Yan X; Zeng C; Zhou G; Cao S
Exp Cell Res; 2022 Aug; 417(2):113192. PubMed ID: 35568072
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
[TBL] [Abstract][Full Text] [Related]
6. ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells.
Valdez BC; Yuan B; Murray D; Ramdial JL; Popat U; Nieto Y; Andersson BS
Oncotarget; 2024 Mar; 15():220-231. PubMed ID: 38484153
[TBL] [Abstract][Full Text] [Related]
7. Targeting CPT1A-mediated fatty acid oxidation sensitizes nasopharyngeal carcinoma to radiation therapy.
Tan Z; Xiao L; Tang M; Bai F; Li J; Li L; Shi F; Li N; Li Y; Du Q; Lu J; Weng X; Yi W; Zhang H; Fan J; Zhou J; Gao Q; Onuchic JN; Bode AM; Luo X; Cao Y
Theranostics; 2018; 8(9):2329-2347. PubMed ID: 29721083
[TBL] [Abstract][Full Text] [Related]
8. MPT0B169, a novel tubulin inhibitor, induces apoptosis in taxol-resistant acute myeloid leukemia cells through mitochondrial dysfunction and Mcl-1 downregulation.
Wang CC; Liu HE; Lee YL; Huang YW; Chen YJ; Liou JP; Huang HM
Tumour Biol; 2016 May; 37(5):6065-72. PubMed ID: 26608370
[TBL] [Abstract][Full Text] [Related]
9. Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia.
Wei W; Huang S; Ling Q; Mao S; Qian Y; Ye W; Li F; Pan J; Lin X; Huang J; Huang X; Zhai Y; Sun J; Jin J
J Transl Med; 2022 Jul; 20(1):299. PubMed ID: 35794605
[TBL] [Abstract][Full Text] [Related]
10. Carnitine-acyltransferase system inhibition, cancer cell death, and prevention of myc-induced lymphomagenesis.
Pacilli A; Calienni M; Margarucci S; D'Apolito M; Petillo O; Rocchi L; Pasquinelli G; Nicolai R; Koverech A; Calvani M; Peluso G; Montanaro L
J Natl Cancer Inst; 2013 Apr; 105(7):489-98. PubMed ID: 23486551
[TBL] [Abstract][Full Text] [Related]
11. High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition.
Bate-Eya LT; den Hartog IJ; van der Ploeg I; Schild L; Koster J; Santo EE; Westerhout EM; Versteeg R; Caron HN; Molenaar JJ; Dolman ME
Oncotarget; 2016 May; 7(19):27946-58. PubMed ID: 27056887
[TBL] [Abstract][Full Text] [Related]
12. High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects.
Li X; Li C; Jin J; Wang J; Huang J; Ma Z; Huang X; He X; Zhou Y; Xu Y; Yu M; Huang S; Yan X; Li F; Pan J; Wang Y; Yu Y; Jin J
EBioMedicine; 2018 Dec; 38():47-56. PubMed ID: 30472087
[TBL] [Abstract][Full Text] [Related]
13. c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia.
Liu S; Qiao X; Wu S; Gai Y; Su Y; Edwards H; Wang Y; Lin H; Taub JW; Wang G; Ge Y
Apoptosis; 2022 Dec; 27(11-12):913-928. PubMed ID: 35943677
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effect of chidamide and venetoclax on apoptosis in acute myeloid leukemia cells and its mechanism.
Li G; Li D; Yuan F; Cheng C; Chen L; Wei X
Ann Transl Med; 2021 Oct; 9(20):1575. PubMed ID: 34790781
[TBL] [Abstract][Full Text] [Related]
15. Carnitine palmitoyltransferase 1A functions to repress FoxO transcription factors to allow cell cycle progression in ovarian cancer.
Shao H; Mohamed EM; Xu GG; Waters M; Jing K; Ma Y; Zhang Y; Spiegel S; Idowu MO; Fang X
Oncotarget; 2016 Jan; 7(4):3832-46. PubMed ID: 26716645
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of carnitine palmitoyl transferase 1A-induced fatty acid oxidation suppresses cell progression in gastric cancer.
Wang L; Li C; Song Y; Yan Z
Arch Biochem Biophys; 2020 Dec; 696():108664. PubMed ID: 33157102
[TBL] [Abstract][Full Text] [Related]
17. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
18. Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells.
Xie S; Jiang H; Zhai XW; Wei F; Wang SD; Ding J; Chen Y
Acta Pharmacol Sin; 2016 Nov; 37(11):1481-1489. PubMed ID: 27569395
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effects of LY294002 and ABT199 on the cell cycle in K562, HL60 and KG1a cells.
Geng Y; Wu W; Zhou L; Li J; Geng Y; Yang Y
Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33846811
[TBL] [Abstract][Full Text] [Related]
20. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
[No Abstract] [Full Text] [Related]
[Next] [New Search]
